Table 2 Number of participants with specific adverse effects and respective percentage to the whole recipients
From: Adverse effects following COVID-19 vaccination in Iran
Variables | Sinopharm | AstraZeneca | Sputnik V | Total | P value |
|---|---|---|---|---|---|
First 72 h, 1st dose | |||||
Local reactions | 55 (3.5%a) | 107 (7.3%) | 363 (20.7%) | 525 (11%) | 0.001 |
General fatigue | 226 (14.5%) | 353 (24.2%) | 776 (44.3%) | 1355 (28.37%) | 0.001 |
Chills and fever | 102 (6.5%) | 657 (45%) | 524 (29.9%) | 1283 (26.86%) | 0.001 |
Dizziness and headache | 64 (4.1%) | 235 (16.1%) | 240 (13.7%) | 539 (11.28%) | 0.001 |
Skeletal pain | 61 (3.9%) | 405 (27.74%) | 603 (34.4%) | 1069 (22.38%) | 0.001 |
Nausea | 8 (0.51%) | 51 (3.49%) | 86 (4.91%) | 145 (3.03%) | 0.001 |
Diarrhea | 2 (0.12%) | 11 (0.75%) | 35 (2%) | 48 (1%) | 0.001 |
Sleepiness | 11 (0.7%) | 17 (1.16%) | 28 (1.6%) | 56 (1.17%) | 0.057 |
Loss of appetite | 0 | 15 (1.02%) | 11 (0.62%) | 26 (0.054%) | 0.001 |
Chest pain and dyspnea | 1 (0.06%) | 11 (0.75%) | 6 (0.34%) | 18 (0.37%) | 0.008 |
Abdominal pain | 0 | 6 (0.41%) | 13 (0.74%) | 19 (0.39%) | 0.003 |
Severe neurological | 0 | 3 (0.2%) | 0 | 3 (0.06%) | 0.033 |
No adverse effects | 1137 (72.7%) | 496 (34%) | 489 (28%) | 2122 (44.4%) | 0.001 |
First 72 h, 2nd dose | |||||
Local reactions | 42 (2.7%) | 50 (3.4%) | 326 (18.6%) | 418 (8.75%) | 0.001 |
General fatigue | 139 (8.9%) | 219 (15%) | 435 (24.8%) | 793 (16.6%) | 0.001 |
Chills and fever | 40 (2.6%) | 109 (7.5%) | 387 (22.1%) | 536 (11.22%) | 0.001 |
Dizziness and headache | 40 (2.6%) | 78 (5.3%) | 126 (7.2%) | 244 (5.1%) | 0.001 |
Skeletal pain | 15 (1%) | 128 (8.8%) | 439 (25.1%) | 582 (12.18%) | 0.001 |
Nausea | 2 (0.12%) | 16 (1.1%) | 33 (1.88%) | 51 (1.06%) | 0.001 |
Diarrhea | 1 (0.06%) | 7 (0.47%) | 8 (0.45%) | 16 (0.33%) | 0.077 |
Sleepiness | 10 (0.63%) | 21 (1.43%) | 18 (1.02%) | 49 (1.02%) | 0.093 |
Loss of appetite | 0 | 1 (0.06%) | 3 (0.17%) | 4 (0.08%) | 0.228 |
Chest pain and dyspnea | 0 | 1 (0.06%) | 2 (0.11%) | 3 (0.06%) | 0.422 |
Abdominal pain | 0 | 1 (0.06%) | 13 (0.74%) | 14 (0.3%) | 0.001 |
Severe neurological | 0 | 0 | 2 (0.11%) | 2 (0.04%) | 0.178 |
No adverse effects | 1295 (82.8%) | 1057 (72.4%) | 719 (41.06%) | 3071 (64.31%) | 0.001 |